Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20252436 | 0.88 | LOXL2 (0.43) | LOXL2ABL1RIN1SMN1; SMN2KMT2A | |
| SCHEMBL20239236 | 0.85 | POLB (0.49) | ABL1RIN1SMN1; SMN2KMT2AGLA | |
| SCHEMBL20239223 | 0.85 | VNN1 (0.47) | SMN1; SMN2KMT2AGLAPTPN1MEN1 | |
| SCHEMBL20239251 | 0.85 | VNN1 (0.44) | SMN1; SMN2KMT2AGLAPTPN1 | |
| SCHEMBL20239220 | 0.83 | LOXL2 (0.45) | LOXL2GLAALDH1A1FFAR1FPR2 | |
| SCHEMBL21924536 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AGLAPTPN1ALDH1A1 | |
| SCHEMBL20239228 | 0.80 | LOXL2 (0.47) | LOXL2ABL1RIN1KMT2AALDH1A1 | |
| SCHEMBL20239159 | 0.78 | LOXL2 (0.45) | LOXL2ABL1RIN1SMN1; SMN2KMT2A | |
| SCHEMBL20239156 | 0.77 | VNN1 (0.46) | SMN1; SMN2KMT2AMEN1FPR2 | |
| SCHEMBL20239196 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AGLAPTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | LOXL2 2081/4885ABL1 3203/4885RIN1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.